ANALYSIS OF HYPERANDROGENBISM AND REPRODUCTIVE LOSS IN WOMEN WITH POLYCYSTIC OVARY SYNDROME

S SHAMAS; F BIBI; S ROSHAN; H SADIA; R BANO

doi:10.54112/bcsrj.v2023i1.593

Authors

S SHAMAS Department of Zoology, Rawalpindi Women University, Rawalpindi, Pakistan
F BIBI Department of Zoology, University of Gujrat, Gujrat, Pakistan
S ROSHAN Department of Zoology, University of Gujrat, Gujrat, Pakistan
H SADIA Department of Biotechnology, Balochistan University of Information Technology, Engineering and Management Sciences
R BANO Department of Zoology, Faculty of Biological Sciences, Quaid-I-Azam University, Islamabad

DOI:

https://doi.org/10.54112/bcsrj.v2023i1.593

Keywords:

Hyperandrogenism, Polycystic Ovarian Syndrome, Infertility

Abstract

The present study aimed to analyze the level of androgen (testosterone) hormone among PCOS females during reproductive age. Hyperandrogenism is an endocrine disorder characterized by high levels of androgen hormones and is associated with reproductive problems predominantly in women. Blood samples of ten normal and fifty PCOS females were taken from Gujrat, Punjab, Pakistan. Information including age, height, weight, cholesterol, glucose, BMI, and any previous medical record was obtained with the patient’s consent. The samples of control and PCOS patients were analyzed through Chemiluminescent Immunoassay (CLIA) for the quantitative determination of testosterone in human serum. The levels of testosterone (mean ± SEM: 2.617 ± 0.1411), glucose (mean ± SEM: 171.5 ± 4.814), cholesterol (mean ± SEM: 209.9 ± 3.674) and BMI (mean ± SEM: ±29.26 ± 1.026) in PCOS was significantly (P<0.0001) high than control subjects (testosterone: mean ± SEM: 1.278 ± 0.1556), (glucose: mean ± SEM: 87.00 ± 6.675), (cholesterol: ± SEM: 96.50 ± 5.480), (BMI: mean ± SEM: 16.21 ± 0.5638) respectively. We conclude that hyperandrogenism may be the cause of infertility in PCOS patients. Hormone replacement therapies may prove to be effective in retrieving the complications induced by hyperandrogenism.

Downloads

Download data is not yet available.

References

Akram, M., & Roohi, N. (2015). Endocrine correlates of polycystic ovary syndrome in Pakistani women. J Coll Physicians Surg Pak, 25(1), 22–6.

Arain, F., Arif, N., & Halepota, H. (2015). Frequency and outcome of treatment in polycystic ovaries related infertility. Pakistan journal of medical sciences, 31(3), 694.Azziz, R. (2016). New insights into the genetics of polycystic ovary syndrome. Nature Reviews Endocrinology, 12(2), 74-75.

Bu, Z., Kuok, K., Meng, J., Wang, R., Xu, B., & Zhang, H. (2012). The relationship between polycystic ovary syndrome, glucose tolerance status, and serum preptin level. Reproductive biology and endocrinology, 10(1), 10.

Chang, R. J., & Dumesic, D. A. (2019). Polycystic ovary syndrome and hyperandrogenic states. In Yen and Jaffe's reproductive endocrinology (pp. 520-555).

Costello, M. F., Misso, M. L., Balen, A., Boyle, J., Devoto, L., Garad, R. M., … & Norman, R. J. (2019). Evidence summaries and recommendations from the international evidence-based guideline for assessing and managing polycystic ovary syndrome: assessment and treatment of infertility. Human reproduction open, 2019(1), hoy021.

Ganie, M. A., Vasudevan, V., Wani, I. A., Baba, M. S., Arif, T., & Rashid, A. (2019). Epidemiology, pathogenesis, genetics & management of polycystic ovary syndrome in India. The Indian Journal of Medical Research, 150(4), 333.

Huang, J., Ding, Y., & Li, Z. (2019). The regulation of the follicular synchronization and sensitivity of rats with PCOS by AMH during prolonged pituitary downregulation. Gene, 721, 144106.

Ortiz-Flores, A. E., Luque-Ramírez, M., & Escobar-Morreale, H. F. (2019). Polycystic ovary syndrome in adult women. Medicina Clínica (English Edition).

Pasquali, R. (2006). Obesity and androgens: facts and perspectives. Fertility and sterility, 85(5), 1319-1340.

Rosenfield, R. L., & Ehrmann, D. A. (2016). The pathogenesis of polycystic ovary syndrome (PCOS): the hypothesis of PCOS as functional ovarian hyperandrogenism revisited. Endocrine reviews, 37(5), 467-520.

Rocha, M. P., Marcondes, J. A., Barcellos, C. R., Hayashida, S. A., Curi, D. D., da Fonseca, Â. M., & Baracat, E. C. (2011). Dyslipidemia in women with polycystic ovary syndrome: incidence, pattern and predictors. Gynecological Endocrinology, 27(10), 814-819.

Simon, S., Rahat, H., Carreau, A. M., Garcia-Reyes, Y., Halbower, A., Pyle, L., ... & Cree-Green, M. (2020). Poor Sleep is Related to Metabolic Syndrome Severity in Adolescents with PCOS and Obesity. The Journal of Clinical Endocrinology & Metabolism.

Shah, M., Ali, A., Malik, M. O., Rehman, F., Badshah, H., Ehtesham, E., & Vitale, S. G. (2019). Treatment with Metformin and Combination of Metformin Plus Pioglitazone on Serum Levels of IL-6 and IL-8 in Polycystic Ovary Syndrome: A Randomized Clinical Trial. Hormone and Metabolic Research, 51(11), 714-722.

Sinha, P., Chitra, T., Papa, D., & Nandeesha, H. (2019). Laparoscopic ovarian drilling reduces testosterone and luteinizing hormone/follicle-stimulating hormone ratio and improves clinical outcome in women with polycystic ovary syndrome. Journal of human reproductive sciences, 12(3), 224.

Yamany, N. A., Yamani, A. N., Althomali, R. O., Alhamyani, R. A., Alwagdani, M. M., Alseraihi, A. A. A., ... & Basakran, G. G. (2020). Polycystic Ovarian Syndrome Overview. EC Microbiology, 15(8), 810-816.

Zhou, L., Ni, Z., Cheng, W., Yu, J., Sun, S., Zhai, D., & Cai, Z. (2020). Characteristic gut microbiota and predicted metabolic functions in women with PCOS. Endocrine Connections, 9(1), 63-73.